We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MAVIRET Abbvie Pty Ltd
Product name
MAVIRET
Sponsor
Accepted date
Apr-2025
Active ingredients
glecaprevir, pibrentasvir
Proposed indication
MAVIRET (glecaprevir, pibrentasvir) is used for treating acute or chronic liver inflammation in adults and children aged 3 years and older caused by hepatitis C virus at a stage of the disease where the liver is still functioning adequately.
Application type
C (new indication)
Publication date
Apr-2025